TScan Therapeutics Announces 75% Workforce Reduction and Strategic Reorganization to Prioritize Solid Tumor Program

TScan Therapeutics, Inc. initiated a strategic reorganization on September 2, 2026, which includes a workforce reduction of approximately 75% of its employees. The company will prioritize the preclinical development of its in vivo solid tumor program and pause further enrollment in its Phase 3 ALLOHA-2™ study of TSC-101. This restructuring is expected to incur approximately $4.1 million in employee-related costs.